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A B S T R A C T 
Crohn's disease (CD) is a type of inflammatory bowel disease (IBD) and its etiology is multifactorial and 
involves a combination of genetic and environmental factors. The interaction of these factors causes an 
imbalance in the microbiota, leading to the activation of several immunological and inflammatory 
mechanisms. From an immunological point of view, there seems to be an involvement of the TIM-
3/galectin-9 pathway and of the autoregulation of LyTh1. The studies show that in patients with CD the 
autoregulation of LyTh1 is lost due to a reduced concentration of galectin-9 and a reduced TIM-3 
expression in LyTh1. This could be one of the reasons for the state of perpetual activation in LyTh1, 
resulting in the chronic inflammatory process.  
© EuroMediterranean Biomedical Journal  2017 
 
1. Introduction 
Crohn's disease (CD) is a type of inflammatory bowel disease (IBD), like 
ulcerative colitis (UC) and indeterminate colitis (IC). This disease is 
characterized by a chronic inflammatory process that can involve every 
segment of the digestive tract from the mouth to the anus; the last ileal 
loop is particularly susceptible to its effects. The chronic inflammatory 
process that occurs in CD leads to profound anatomical and functional 
changes of the mucosa, ranging from simple superficial ulcerations to 
perforations. The disease can cause various symptoms, such as abdominal 
pain, often bloody diarrhea, dehydration, intermittent and prolonged fever, 
malabsorption of nutrients, weight loss, and sometimes anemia. Further 
common complications include stenosis, fissures and perianal fistulas (1-
4). 
The etiology of CD is multifactorial and involves a combination of 
genetic and environmental factors. A current key point of interest is 
intestinal dysbiosis (5). Indeed, the intestinal microbiota of subjects with 
CD show a dysbiosis characterized by changes in Firmicutes and 
Proteobacteria phyla (6). 
Dietary habits, such as a diet rich in sugars and fats (2,3), smoking (2,7), 
and use of antibiotics (8) are some of the environmental factors that can 
influence the composition of the intestinal microbiota. The interaction of 
these factors causes an imbalance in the microbiota, leading to the 
activation of several immunological and inflammatory mechanisms. Such 
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mechanisms include the alteration of tight junctions in the intestinal 
epithelial barrier (9) and the establishment of a chronic inflammatory 
state, characterized by the release of various chemical mediators of 
inflammation, such as heat shock proteins (HSP), interleukins and COX-2 
causing the release of arachidonic acid metabolites (10-14). 
From an immunological point of view, there seems to be an involvement 
of the TIM-3/galectin-9 pathway, which will be discussed in detail below. 
 
2. TIM-3/galectin-9 pathway and CD 
The enzymes of enteric bacteria induce tight junction alterations in the 
epithelium of the intestinal mucosa, promoting the passage of bacteria to 
the lamina propria, where the gut-associated lymphoid tissue (GALT) is 
located (15). GALT contains different cell types that produce cytokines, 
which activate cells and determine the differentiation of naive T 
lymphocytes (LyT) into LyTh1, believed to be the main protagonists of 
the immune response in CD (16-18). LyTh1 produce interferon gamma 
(IFN-y) and matrix metallo proteinases (MMPs), which cause an 
amplified permeabilization of the epithelial barrier, thus intensifying the 
tissue damage and causing the inflammatory state to become chronic (15). 
The switch-off mechanism of LyTh1 is regulated through the interaction 
between two molecules produced by the lymphocytes themselves: a 
membrane protein called T-cell immunoglobulin and mucin domain, or 
TIM-3 and its ligand, a glycoprotein called galectin-9 (19). It has been 
shown that the interaction between TIM-3 and galectin-9 in LyTh1 
downregulates the production of inflammatory cytokines, such as IFN-y, 
IL-17, IL-2, and IL-6 (12,13,20), by inducing peripheral tolerance (19) 
and mediating apoptosis inhuman and murine Th1 (21). However, the 
mechanisms through which TIM-3/galectin-9 interaction causes an 
increase in the transcription of cytokines and apoptosis of T-cells are still 
somewhat uncertain. Currently, it is thought that this interaction causes 
the entry of calcium into the cells, thus inducing apoptosis (22). The TIM-
3/galectin-9 pathway appears to be an important factor in the pathogenesis 
of CD. TIM-3 is a surface molecules electively expressed in LyTh1 of the 
intestinal mucosa. Galectin-9 binding regulates these lymphocytes in the 
healthy mucosa. It has been observed that in patients with CD, the 
autoregulation of LyTh1 is lost due to a reduced concentration of galectin-
9 and a reduced TIM-3 expression in LyTh1 (19). This could be one of the 
reasons for the state of perpetual activation in LyTh1, resulting in the 
chronic inflammatory process. This hypothesis opens up a possible 
pharmacological solution for disorders characterized by TIM-3/galectin-9 
alterations, with the development of drugs targeted at increasing the 
amount of galectin-9 in patients with CD (23). 
 
3. Conclusions 
These data suggest that TIM-3 plays a pro-apoptotic role in 
immunosuppression and production of pro-inflammatory cytokines, 
dependent on the concentration of galectin-9. Based on these 
observations, drugs that induce the interaction between TIM-3 and 
galectin-9 could be created, aimed at reducing the inflammatory processes 
characteristic of CD, and the consequent chronicization. Further studies 
are needed to better determine the clinical and therapeutic aspects of TIM-
3/galectin-9 binding. 
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